Part of the challenge for THInteresting article. Here is the concluding paragraph:
The bottom line is that achieving and maintaining relevance with the top buyside funds in an ever-expanding universe of investable opportunities only comes through hard work and planning, plus a healthy dose of good fortune in R&D. This buyside relevancy is critical to getting the attention required to access funding at a reasonable cost of capital – which is an existential requirement for success in loss-making R&D-stage biotech over the long term.
https://lifescivc.com/2021/06/biotechs-relevancy-challenge-in-an-expanding-universe/